Nurix (NRIX) stays a Strong Buy as bexobrutideg posts 83% ORR in r/r CLL and lands a $2.3B Roche deal—review the catalysts, ...

Researchers at the Hebrew University of Jerusalem have developed a cellulose-based scaffold that reduces the quantity of ...

For cultured meats to succeed in the market, they will have to prove themselves cost-effective to produce, be as food-safe as ...

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from SanofiWATERTOWN, Mass., ...

Plants are undeniably one of nature's most promising sources of new medicines, with monoterpenoid indole alkaloids (MIAs) ...

Researchers in the lab of Cancer Center at Illinois (CCIL) member Xing Wang have discovered the influential role of ...

Bexobrutideg leverages targeted protein degradation to eliminate BTK, potentially overcoming resistance mutations and ...

First-in-human Phase 1 trial evaluating KT-485 (SAR447971) initiated, triggering a $20 million milestone payment from Sanofi WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, ...

This video follows a busy day on site, showcasing the work, planning, and teamwork involved in professional scaffolding ...

Before you try extreme measures to lose weight rapidly, you must factor in the toll it will take on your skin and hair health ...

Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of B-cell targeted ...

Johnson & Johnson’s Firelink degrader antibody conjugate strategy seeks tumor-selective delivery of degraders for KRAS-driven solid tumors, potentially overcoming toxicity and efficacy ceilings of ...